


Stabilis



Insulin



Varunamn

Actrapid	Belgien, Danmark, Finland, Frankrike, Grekland, Irland, Italien, Jugoslavien, Kroatien, Nederländerna, Norge, Österrike, Polen, Portugal, Schweiz, Slovenien, Spanien, Storbritannien, Sverige, Turkiet, Ungern
Bioinsugen	Chile
Biosulin	ryska
Gensulin	Polen
Humaject	Kroatien, Polen, Slovenien
Humaplust	Spanien
Humasulin	Österrike, Schweiz
Humasulina	Spanien
Humulin R	Texte introuvable (616,), Danmark, Förenta Staterna, Grekland, Kanada, Kroatien, Polen, Slovenien, Storbritannien, Sydafrikanska republiken, Turkiet
Humuline	Belgien, Nederländerna
Insuman	Texte introuvable (616,), Danmark, Finland, Frankrike, Irland, Nederländerna, Norge, Österrike, ryska, Schweiz, Storbritannien, Sverige
Isuhuman	Portugal
Novolin	Kanada
Umuline	Frankrike
Velosulin	Texte introuvable (616,), Belgien, Frankrike, Österrike
Velosuline	Förenta Staterna



Lösningars stabilitet

PVC		0,1 UI/ml	2-8°C		8			2091
PVC		0,1 UI/ml	25°C		24			2091
PVC		0,1 UI/ml	37°C		24			2091
PVC		0,004 UI/ml	25°C		24			2164
PVC		0,01 UI/ml	25°C		24			2164
PVC		0,02 UI/ml	25°C		24			2164
PVC		0,04 UI/ml	25°C		24			2164

		0,01 UI/ml	25°C		6			2164
		0,02 UI/ml	25°C		6			2164
		0,04 UI/ml	25°C		6			2164
		100 UI/ml	37°C		48			803
		0,01 UI/ml	25°C		6			2164
		0,02 UI/ml	25°C		6			2164
		0,04 UI/ml	25°C		6			2164
		100 UI/ml	3-5°C		28			468
		1 UI/ml	2-6°C		180			3224
		1 UI/ml	2-8°C		21			4635
		1 UI/ml	20-25°C		48			4635
		1 UI/ml	23-27°C		30			3224
		100 UI/ml	3-5°C		28			468
		500 UI/ml	4°C		28			4309



Stabilitet i blandningar

									
		0,8 UI/ml	22°C-23°C		Milrinone lactate : 0,2 mg/ml		4		813
		1 UI/ml	25°C		Ranitidine hydrochloride : 1 mg/ml		1		208



Faktorer som påverkar stabiliteten

				857
				1091
				208
				464
				1175
				1242
				2091
				3310
				1242
				1245



Kompatibilitet

		Insulin : 1 UI/ml Amiodarone hydrochloride : 12,5 mg/ml		4119
		Insulin : 1 UI/ml Amiodarone hydrochloride : 4.8 mg/ml		295
		Insulin		5044
		Insulin : 1 UI/ml Acetylsalicylic acid lysinate : 10 mg/ml		4698
		Insulin : 1 UI/ml Alprostadil : 20 µg/ml		4651
		Insulin : 1 UI/ml Alprostadil : 20 µg/ml		4491
		Insulin : 2 UI/ml Amiodarone hydrochloride : 15 mg/ml		3823
		Insulin : 1 UI/ml Amiodarone hydrochloride : 6 mg/ml		4698
		Insulin : 1 UI/ml Amiodarone hydrochloride : 25 mg/ml		4119
		Insulin Amiodarone hydrochloride		3464
		Insulin : 2 UI/ml Amiodarone hydrochloride : 15 mg/ml		3823
		Insulin : 1 UI/ml Amiodarone hydrochloride : 0,6 >> 9,75 mg/ml		4119
		Insulin : 1 UI/ml Amoxicillin sodium : 20.83 & 83.3 mg/ml		4254
		Insulin : 100 UI/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
		Insulin : 0.2 UI/ml Ampicillin sodium : 20 mg/ml		129
		Insulin : 0.2 UI/ml Ampicillin sodium - sulbactam sodium : 30 mg/ml		129
		Insulin : 0.2 UI/ml Aztreonam : 20 mg/ml		129
		Insulin : 1 UI/ml Bretylium tosylate : 1 mg/ml		1193
		Insulin : 1 UI/ml Bretylium tosylate : 1 mg/ml		1193
		Insulin : 100 UI/ml Caffeine : 10 mg/ml		3964
		Insulin : 0.2 UI/ml Caffeine : 10 mg/ml		4837
		Insulin : 0,2 UI/ml Caffeine citrate : 20 mg/ml		4837
		Insulin : 1 UI/ml Caspofungin acetate : 0.5 mg/ml		2233
		Insulin		4567

		Insulin : 100 UI/ml Calcium chloride : 100 mg/ml	Ø	4904
		Insulin : 100 UI/ml Calcium gluconate : 100 mg/ml	Ø	4904
		Insulin : 1 UI/ml Caspofungin acetate : 0,7 mg/ml	▲	2247
		Insulin : 0.2 UI/ml Cefazolin sodium : 20 mg/ml	▲	129
		Insulin : 100 UI/ml Cefepime dihydrochloride : 125 mg/ml	💧	2141
		Insulin : 1 UI/ml Cefiderocol sulfate tosylate : 20 mg/mL	◆	4528
		Insulin : 1 UI/ml Cefiderocol sulfate tosylate : 20 mg/mL	▲	4528
		Insulin : 1 UI/ml Cefotaxime sodium : 83.3 mg/ml	◆	4254
		Insulin : 1 UI/ml Cefotaxime sodium : 83.3 mg/ml	▲	4254
		Insulin : 1 UI/ml Ceftaroline fosamil : 2,22 mg/ml	▲	3249
		Insulin : 1 UI/ml	📊	1415
		Insulin : 1 UI/ml Ceftaroline fosamil : 2,22 mg/ml	◆	3249
		Insulin : 1 UI/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
		Insulin : 100 UI/ml Ceftazidime : 125 mg/ml	💧	2141
		Insulin : 1 UI/ml Ceftobiprole medocaril sodium : 2 mg/ml	▲	2269
		Insulin Ceftobiprole medocaril sodium		4650
		Insulin : 1 UI/ml	📊	4924
		Insulin : 2 UI/ml	📖	939
		Insulin : 1 UI/ml	📖	301
		Insulin : 100 UI/ml	RL	4603
		Insulin : 1 UI/ml Ceftobiprole medocaril sodium : 2 mg/ml	◆	2269
		Insulin : 1 UI/ml Ceftobiprole medocaril sodium : 2 mg/ml	RL	2269
		Insulin : 1 UI/ml Ceftolozane / tazobactam : 10/5 mg/ml	▲	3828
		Insulin : 1 UI/ml Ceftolozane / tazobactam : 10/5 mg/ml	◆	3828
		Insulin : 0.1 UI/ml Cimetidine hydrochloride : 1.2 & 5 mg/ml	◆	1201
		Insulin : 0.1 UI/ml Cimetidine hydrochloride : 1.2 & 5 mg/ml	▲	1201
		Insulin : 2 UI/ml Cisatracurium besylate : 5 mg/ml	▲	3823

	Insulin : 1 UI/ml Cisatracurium besylate : 1 mg/ml		3429
	Insulin : 1 UI/ml Clonidine hydrochloride : 0.0075 mg/ml		1506
	Insulin : 1 UI/ml Clonidine hydrochloride : 0.0075 mg/ml		1506
	Insulin : 100 UI/ml Cloxacillin sodium : 100 mg/ml		3012
	Insulin : 1 UI/ml Co-trimoxazole : 3.2/0.64 & 80/16 mg/ml		4254
	Insulin : 1 UI/ml Co-trimoxazole : 3.2/0.64 & 80/16 mg/ml		4254
	Insulin Cytarabine		3580
	Insulin : 2 UI/ml Diclofenac : 3 mg/ml		3823
	Insulin : 0.4 UI/ml Diltiazem hydrochloride : 5 mg/ml		198
	Insulin : 100 UI/ml Diltiazem hydrochloride : 1 & 5 mg/ml		198
	Insulin : 1 UI/ml Dobutamine hydrochloride : 8 mg/ml		1506
	Insulin : 1 UI/ml Dobutamine hydrochloride : 1 mg/ml		1058
	Insulin : 1 UI/ml Dobutamine hydrochloride : 1 mg/ml		1058
	Insulin : 100 UI/ml Dobutamine hydrochloride : 2 mg/ml		1041
	Insulin : 1 UI/ml Dobutamine hydrochloride : 8 mg/ml		1506
	Insulin : 1 UI/ml Dopamine hydrochloride : 8 mg/ml		1506
	Insulin : 100 UI/ml Dopamine hydrochloride : 3,2 mg/ml		4389
	Insulin : 1 UI/ml Dopamine hydrochloride : 8 mg/ml		1506
	Insulin : 1 UI/ml Dopamine hydrochloride : 3.2 mg/ml		295
	Insulin : 1 UI/ml Doripenem : 5 mg/ml		2262
	Insulin : 1 UI/ml Doripenem : 5 mg/ml		2262
	Insulin : 1 UI/ml Doxapram hydrochloride : 2 mg/ml		1802
	Insulin : 1 UI/ml Eravacycline : 0,6 mg/ml		4434
	Insulin : 1 UI/ml Esmolol hydrochloride : 40 mg/ml		295
	Insulin : 1 UI/ml Esomeprazole sodium : 0.32 mg/ml		1506
	Insulin : 1 UI/ml Esomeprazole sodium : 0.32 mg/ml		1506

	Insulin : 0.03 UI/ml Famotidine : 0.2 mg/ml		398
	Insulin : 1 UI/ml Fosfomycin : 30 mg/ml		4055
	Insulin : 1 UI/ml Fosfomycin : 30 mg/ml		4055
	Insulin		5044
	Insulin : 2 UI/ml Furosemide : 10 mg/ml		3823
	Insulin : 2 UI/ml Furosemide : 10 mg/ml		3134
	Insulin : 1 UI/ml Furosemide : 10 mg/ml		3210
	Insulin Furosemide		3465
	Insulin : 0.2 UI/ml Gentamicin sulfate : 1.2 >> 2 mg/ml		129
	Insulin : 1 UI/ml Glycerophosphate disodium		4332
	Insulin : 2 UI/ml Haloperidol lactate : 0.5 mg/ml		3823
	Insulin : 0.2 UI/ml Heparin sodium : 60 UI/ml		129
	Insulin : 2 UI/ml Heparin sodium : 500 UI/ml		3823
	Insulin : 0.1 UI/ml Ibuprofen lysinate : 10 mg/ml		4419
	Insulin : 1 UI/ml Ibuprofen lysinate : 10 mg/ml		4419
	Insulin : 1 UI/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml		4433
	Insulin : 1 UI/ml Indomethacin sodium trihydrate : 1 mg/ml		467
	Insulin : 1 UI/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
	Insulin : 1 UI/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
	Insulin : 1 UI/ml Isosorbide dinitrate : 1 mg/ml		4698
	Insulin : 100 UI/ml Ketamine hydrochloride : 50 mg/ml		2109
	Insulin : 1 UI/ml Labetalol hydrochloride : 5 mg/ml		295
	Insulin : 1 UI/ml Levofloxacin : 5 mg/ml		1072
	Insulin : 100 UI/ml Levofloxacin : 5 mg/ml		1072
	Insulin : 1 UI/ml Lidocaine hydrochloride : 2 mg/ml		619
	Insulin : 1 UI/ml Lidocaine hydrochloride : 2 mg/ml	RL	619

	Insulin : 1 UI/ml Lidocaine hydrochloride : 2 mg/ml		619
	Insulin : 1 UI/ml Linezolid : 2 mg/ml		4254
	Insulin : 0.2 UI/ml Magnesium sulfate : 40 mg/ml		129
	Insulin : 0.2 UI/ml Meropenem : 1 & 50 mg/ml		266
	Insulin : 1 UI/ml Meropenem : 1 & 20 mg/ml		266
	Insulin : 100 UI/ml Meropenem : 50 mg/ml		4319
	Insulin : 1 UI/ml Methadone hydrochloride : 0.2 mg/ml		1506
	Insulin : 1 UI/ml Methadone hydrochloride : 0.2 mg/ml		1506
	Insulin : 1 UI/ml Micafungin : 1.5 mg/ml		2108
	Insulin : 1 UI/ml Midazolam hydrochloride : 4 mg/ml		1506
	Insulin : 2 UI/ml Midazolam hydrochloride : 2.1 mg/ml		3823
	Insulin : 1 UI/ml Midazolam hydrochloride : 4 mg/ml		1506
	Insulin : 1 UI/ml Midazolam hydrochloride : 1 mg/ml		295
	Insulin : 2 UI/ml Milrinone lactate : 0.8 mg/ml		813
	Insulin : 1 UI/ml Morphine sulfate : 1 mg/ml		295
	Insulin : 0.2 UI/ml Morphine sulfate : 1 mg/ml		406
	Insulin : 0.2 UI/ml Morphine sulfate : 5 mg/ml		129
	Insulin : 100 UI/ml N-acetylcysteine : 200 mg/ml		3766
	Insulin : 0.2 UI/ml Nafcillin sodium : 20 & 40 mg/ml		129
	Insulin : 100 UI/ml Naloxone hydrochloride : 0.4 mg/ml		3408
	Insulin : 1 UI/ml Nefopam : 0,16 mg/ml		4698
	Insulin Nesiritide		5048
	Insulin : 2 UI/ml Nitroglycerin : 0.2 mg/ml		3823
	Insulin : 2 UI/ml Nitroglycerin : 0.2 mg/ml		3823
	Insulin : 1 UI/ml Nitroglycerin : 0.2 mg/ml		295
	Insulin : 1 UI/ml Nitroprusside sodium : 0.2 mg/ml		295

		Insulin : 1 UI/ml Norepinephrine bitartrate : 0.32 mg/ml		1506
		Insulin : 1 UI/ml Norepinephrine bitartrate : 0.32 mg/ml		1506
		Insulin : 1 UI/ml Norepinephrine bitartrate : 0.064 mg/ml		295
		Insulin : 1 UI/ml Oritavancin : 0.8 >>2 mg/ml		3152
		Insulin : 1 UI/ml Ornidazole : 31.25 mg/ml		4254
		Insulin : 0.2 UI/ml Oxytocin : 0.02 UI/ml		129
		Insulin Pantoprazole sodium		2090
		Insulin : 5 >> 50 UI/ml Pantoprazole sodium : 0.16 >> 0.8 mg/ml		1902
		Insulin : 1 UI/ml Pantoprazole sodium : 1 mg/ml		4698
		Insulin : 1 UI/ml Paracetamol : 10 mg/ml		4698
		Insulin : 100 UI/ml Paracetamol : 10 mg/ml		4742
		Insulin : 0,2 UI/ml Pentoxifyllin : 5 mg/ml		4543
		Insulin : 0.2 UI/ml Pethidine hydrochloride : 50 mg/ml		129
		Insulin : 0.2 UI/ml Pethidine hydrochloride : 10 mg/ml		406
		Insulin : 1 UI/ml Phloroglucinol : 10 mg/ml		4698
		Insulin : 1 UI/ml Piperacillin sodium / tazobactam : 166/20.83 mg/ml		4254
		Insulin : 1 UI/ml Piperacillin sodium / tazobactam : 166/20.83 mg/ml		4254
		Insulin : 1 UI/ml Plazomicin sulfate : 24 mg/ml		4145
		Insulin : 40 UI/ml Potassium chloride : 40 mEq/l		730
		Insulin : 40 UI/ml Potassium chloride : 40 mEq/l	RL	730
		Insulin : 40 UI/ml Potassium chloride : 40 mEq/l		730
		Insulin Potassium phosphate		3781
		Insulin : 1 UI/ml Propofol : 10 mg/ml		300
		Insulin : 1 UI/ml Remifentanyl hydrochloride : 120 µg/ml		3176
		Insulin : 1 UI/ml Remifentanyl hydrochloride : 100 µg/ml		4698
		Insulin Rocuronium bromide		3564

		Insulin : 100 UI/ml Salbutamol sulfate : 1 mg/ml		3216
		Insulin : 0.2 UI/ml Sildenafil citrate : 0,6 mg/ml		4845
		Insulin : 2 UI/ml Sodium bicarbonate : 84 mg/ml		3212
		Insulin : 2 UI/ml Sodium bicarbonate : 84 mg/ml		3823
		Insulin Sodium bicarbonate		3466
		Insulin : 100 UI/ml Sugammadex : 100 mg/ml		3372
		Insulin : 0,1 UI/ml Tacrolimus : 1000 µg/ml		479
		Insulin : 1 UI/ml Tedizolid phosphate : 0.8 mg/ml		3827
		Insulin : 100 UI/ml Temocilline : 83.33 mg/ml		2231
		Insulin : 0.2 UI/ml Terbutaline sulfate : 0.02 mg/ml		129
		Insulin Theophylline		5054
		Insulin Thiopental sodium : 25 mg/ml		3767
		Insulin : 0.2 UI/ml Ticarcillin / clavulanic acid : 31 mg/ml		129
		Insulin : 2 UI/ml Tirofiban : 250 µg/ml		3823
		Insulin : 0.2 UI/ml Tobramycin sulfate : 1.6 & 2 mg/ml		129
		Insulin : 2 UI/ml Urapidil : 5 mg/ml		3823
		Insulin : 100 UI/ml Vancomycin hydrochloride : 10 mg/ml		3385
		Insulin : 0.2 UI/ml Vancomycin hydrochloride : 4 mg/ml		129
		Insulin : 1 UI/ml Vasopressin : 0.2 UI/ml		2017
		Insulin : 0,2 UI/ml Verapamil hydrochloride : 0,08 mg/ml		706
		Insulin		5044



Administreringssätt





Hänvisningar

	Typ	Publikation
129	tidningen	Smythe M, Malouf E. Visual compatibility of insulin with secondary intravenous drugs in admixtures. Am J Hosp Pharm 1991 ; 48: 125-126.
198	tidningen	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
208	tidningen	Nolan PE, Hoyer GL, Ledoux JH, Fox JL. Stability of ranitidine hydrochloride and human insulin in 0.9% sodium chloride injection. Am J Health-Syst Pharm 1997 ; 54: 1304-1306.
266	tidningen	Patel PR. Compatibility of meropenem with commonly used injectable drugs. Am J Health-Syst Pharm 1996 ; 53: 2853-2855.
295	tidningen	Yamashita SK, Walker SE, Choudhury T, Iazzetta J. Compatibility of selected critical care drugs during Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1048-1051.
300	tidningen	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	tidningen	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
398	tidningen	Jay GT, Fanikos J, Souney PF. Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1556-1557.
406	tidningen	Smythe MA, Patel MA, Gasloli RA. Visual compatibility of narcotic analgesics with selected intravenous admixtures. Am J Hosp Pharm 1990 ; 47: 819-820.
464	tidningen	Furberg H, Kruse Jensen A, Salbu B. Effect of pretreatment with 0.9% sodium chloride or insulin solutions on the delivery of insuline from an infusion system. Am J Hosp Pharm 1986 ; 43: 2209-2213.
467	tidningen	Ishisaka DY, van Vleet J, Marquardt E. Visual compatibility of indomethacin sodium trihydrate with drugs given to neonates by continuous infusion. Am J Hosp Pharm 1991 ; 48: 2442-2443.
468	tidningen	Tarr BD, Campbell RK, Workman TM. Stability and sterility of biosynthetic human insulin stored in plastic insulin syringes for 28 days. Am J Hosp Pharm 1991 ; 48: 2631-2634.
479	tidningen	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
619	tidningen	Kirschenbaum HL, Aronoff W, Perentesis GP, Plitz GW, Cutie AJ. Stability and compatibility of lidocaine hydrochloride with selected large-volume parenterals and drugs additives. Am J Hosp Pharm 1982 ; 39: 1013-1015.
706	tidningen	Cutie MR. Compatibility of verapamil hydrochloride with other additives. Am J Hosp Pharm 1981 ; 38: 231.

730	tidningen	Allen LV, Saul Levinson R, Phisutsinthop D. Compatibility of various admixtures with secondary additives at Y-injection site of intravenous administration sets. Am J Hosp Pharm 1977 ; 34: 939-943.
803	tidningen	Lougheed WD, Weymouth AB, Zinman B, Bernstein EA, Strack TR, Korbas AM, Janis LJ, Frank BH. Stability of insulin lispro in insulin infusion systems. Diabetes Care 1997 ; 20: 1061-1065.
813	tidningen	Akkermann SR, Zhang H, Mullins RE, Yaughn K. Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions. Am J Health-Syst Pharm 1999 ; 56: 63-68.
857	tidningen	Kanke M, Eubanks JL, DeLuca PP. Binding of selected drugs to a “treated” inline filter. Am J Hosp Pharm 1983 ; 40: 1323-1328.
939	tidningen	Gilbar PJ, Groves CF. Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection. Aust J Hosp Pharm 1994 ; 24: 167-170.
1041	tidningen	Hasegawa GR, Eder JF. Visual compatibility of dobutamine hydrochloride with other injectable drugs. Am J Hosp Pharm 1984 ; 41: 949-951.
1058	tidningen	Kirschenbaum HL, Aronoff W, Piltz GW, Perentesis GP, Cutie AJ. Compatibility and stability of dobutamine hydrochloride with large-volume parenterals and selected additives. Am J Hosp Pharm 1983 ; 40: 1690-1691.
1072	tidningen	Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA. Compatibility of levofloxacin with 34 medications during simulated Y-site administration. Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1091	tidningen	Petty C, Cunningham NL. Insulin adsorption by glass infusion bottles, polyvinylchloride infusion containers, and intravenous tubing. Anesthesiology 1974 ; 40: 400-404.
1175	tidningen	Hirsch JI, Wood JH, Thomas RB. Insulin adsorption to polyolefin infusion bottles and polyvinyl chloride administration sets. Am J Hosp Pharm 1981 ; 38: 995-997.
1193	tidningen	Perentesis GP, Plitz GW, Kirschenbaum HL, Navalakha P, Aronoff W, Cutie AJ. Stability and visual compatibility of bretylium tosylate with selected large-volume parenterals and additives. Am J Hosp Pharm 1983 ; 40: 1010-1012.
1201	tidningen	Yuhaz EM, Lofton FT, Rosenberg HA, Mayron D, Baldinus JG. Cimetidine hydrochloride compatibility III: Room temperature stability in drug admixtures. Am J Hosp Pharm 1981 ; 38: 1919-1922.
1242	tidningen	Tol A, Quik RFP, Thyssen JHH. Adsorption of human and porcine insulins to intravenous administration sets. Pharm Weekbl [Sci] 1988 ; 10: 213-216.
1245	tidningen	Doglietto GB, Bellantone R, Bossola M, Perri V, Ratto C, Pacelli F, Sofo L, Migliore A, Manna R, Crucitti F. Insulin adsorption to three-liter ethylen vinyl acetate bags during 24-hour infusion. JPEN 1989 ; 13: 539-543.
1415	tidningen	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1506	tidningen	Lopez-Cabezas C, Guerrero L, Molas G, Anglada H, Soy D. Physicochemical compatibility of high concentration drugs usually Y-site administered in intensive care units. EJHP 2015 ;22:107-112.
1802	tidningen	Bell MS, Nolt DH. Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive care nursery. Am J Health-Syst Pharm 2003 ; 60: 193-194.

1902	tidningen	Walker SE, Wyllie A, Law S. Physical compatibility of pantoprazole with selected medications during simulated Y-site administration. Can J Hosp Pharm 2004 ; 57, 2: 90-96.
2017	tidningen	Barker B, Feddema S, Rusho WJ, Dengg R. Visual compatibility of vasopressin with other injectable drugs. Am J Health-Syst Pharm 2005 ; 62: 1969-1976.
2090	tidningen	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2091	tidningen	Lim SC, Roberts MJ, Paech MJ, Peng L, Jones A. Stability of insulin aspart in normal saline infusion. J Pharm Pract and Res 2004 ; 34: 11-13.
2108	tidningen	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2109	tidningen	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2141	tidningen	Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM. Stability and compatibility study of cefepime in comparaison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. J Antimicrob Chemother 2003 ; 51: 651-658.
2164	tidningen	Voges M, Divinop-Filho JC, Faict D, Somers F, Vermeulen P. Compatibility of insulin over 24 hours in standard and bicarbonate-based peritoneal dialysis solutions contained in bags made of different materials. Perit Dial Int 2006 ; 26, 4: 498-502.
2231	tidningen	de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008 ; 61, 2: 382-388.
2233	tidningen	Condie C.K, Tyler L.S, Barker B, Canann D.M. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2247	tidningen	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	tidningen	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administration Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	tidningen	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
3012	tidningen	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3134	tidningen	Perez Jua En, Maqueda Palau M, Arévalo Rubert Mt, Ribas Nicolau B, Amoros Cerdà SM. Compatibilidad visual y física de la furosemda en mezclas intravenosas para perfusión continua. Enferm Intensiva 2010 ; 21: 96-103.
3152	tidningen	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.

3176	affisch	Humbert Delaloye V, Berger M, Voirol P, Pannatier A. Compatibilité du Remifentanyl avec d'autres médicaments injectables : influence du soluté. 16èmes JFSPH, Sion, 18-19 novembre 2010
3210	tidningen	Jasti Bhaskara R, Saraf Poonam. Compatibility of Parenteral Furosemide with Seventeen Secondary Drugs Used in Standard Concentrations. Int J Pharm Compound 2011 ; 15, 3: 259-261.
3212	tidningen	Ribas Nicolau, B.; Pérez Juan, E.; Amor's Cerdá, S.M.; Arvalo Rubert, M.J.; Maqueda Palau, M. Compatibilidad física del bicarbonato sódico con fármacos de uso frecuente en la unidad de cuidados intensivos. Enferm Intensiva 2011 ;22:78-82.
3216	tidningen	Legrís ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3224	tidningen	Fleury-Souverain S, Sigríst T, Griffiths W, Ing H, Matthey B; Sadeghipour F, Bonnabry P. The stability of soluble insulin in plastic syringes EJHP Science 2011 ; 1: 3-6.
3249	tidningen	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3310	tidningen	Greenwood B.C, Chesnick M.A, Szumita P.M, Caryn Belisle C, Cotugno M. Stability of Regular Human Insulin Extemporaneously Prepared in 0.9% Sodium Chloride in a Polyvinyl Chloride Bag. Hosp Pharm 2012 ; 47, 5: 367-370.
3372	tidningen	Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S. Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine. Rev Bras Anesthesiol 2013 ; 63, 1: 163-166.
3385	tidningen	Raverdi V, Ampe E, Hecq JD, Tulkens PM. Stability and compatibility of vancomycin for administration by continuous infusion. J Antimicrob Chemother 2013 ; 68: 1179-1182.
3408	tidningen	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3429	tidningen	Foushee J.A, Fox L.M, Gormley L.R, Lineberger M.S. Physical compatibility of cisatracurium with selected drugs during simulated Y-site administration Am J Health-Syst Pharm 2015 ; 72:483-486
3464	tidningen	Monica Maqueda-Palau, Eva Pérez-Juan, Maria Josep Arévalo-Rubert, Sylvia Monica Amorós-Cerda, Bàrbara Ribas-Nicolau. Compatibilidad física de la amiodarona en perfusión continua Enferm Clin 2011 21:25-29.
3465	tidningen	E. Pérez Juan, M. Maqueda Palau, M. Arvalo Rubert, B. Ribas Nicolau, S.M. Amor's Cerdá. Compatibilidad visual y física de la furosemida en mezclas intravenosas para perfusión continua. Enferm Intensiva 2010 ;21:96-103.
3466	tidningen	B. Ribas Nicolau, E. Pérez Juan, S.M. Amor's Cerdá, M.J. Arvalo Rubert, M. Maqueda Palau. Compatibilidad física del bicarbonato sódico con fármacos de uso frecuente en la unidad de cuidados intensivos Enferm Intensiva 2011 ;22:78-82.
3564	Laboratorium	Rocuronium B Braun - Résumé des caractéristiques du produit. B Braun 2012
3580	Laboratorium	Cytarabine Accord - Résumé des caractéristiques du produit Accord Healthcare France 2016
3766	tidningen	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.

3767	tidningen	Legrís M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3781	tidningen	Humbert-Delaloye V, Berger-Gryllaki M, Voirol P, Testa B, Pannatier A Screening for physicochemical incompatibilities of intravenous drugs in intensive care units: the case of monobasic potassium phosphate and furosemide. EJHP 2015 ;22:1 56-58
3823	tidningen	Juan E.P, Palau M.M, Cerdá S.A, Rubert M.A, Nicolau B.R. Compatibilité physique de médicaments administrés dans l'unité de soins intensifs Pharmactuel 2015 ; 48, 3 : 146-152.
3824	tidningen	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	affisch	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	affisch	Thabit A.K, Hamada Y, Nicolau D.P. Ceftazolin/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	affisch	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavuconazole sulfate during simulated Y-site administration. ASHP Midyear 2015
3964	tidningen	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4055	tidningen	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4119	affisch	Marcoz N, Ing H, Sautter AM, Saadi JF, Roulin JF, Bonnabry P. Stabilité et compatibilité de solutions injectables d'amiodarone (Cordarone®) Hôpitaux Universitaire de Genève 2004
4145	tidningen	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4254	tidningen	D'Huart E, Vigneron J, Demoré B. Physical Compatibility of Intravenous Drugs Commonly Used in Intensive Care Units: An Observational Study and Physical Compatibility Laboratory Tests on Anti-Infective Drugs Pharmaceutical Technology in Hospital Pharmacy 2019 ;4,1:29-40
4309	tidningen	Lull M.E, Piacentino J.J, Traina A.N. Stability of U-500 regular insulin in prefilled syringes J Am Pharm Assoc 2013 ; 53, 3: 304-306.
4319	tidningen	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4332	affisch	Compatibilité de Glycophos® avec d'autres médicaments administrés en perfusion aux soins intensifs (SI) Compatibilité de Glycophos® avec d'autres médicaments administrés en perfusion aux soins intensifs (SI). JFSPH 2019 2019

4389	tidningen	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4419	tidningen	Holt R.J, Siegert S.W.K, Krishna A. Physical Compatibility of Ibuprofen Lysine Injection with Selected Drugs During Simulated Y-site Injection. J Pediatr Pharmacol Ther 2008 ; 13, 3: 155-161.
4433	tidningen	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4434	tidningen	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4491	tidningen	De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pilar P, De Miguel M, Campino A. Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units. Eur J Pediatr 2020
4528	tidningen	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4543	tidningen	Senarathna G, Strunk T, Petrovski M, Batty K. Physical compatibility of pentoxifylline and intravenous medications. Archives of Disease in Childhood 2018 ;104:292–295.
4567	tidningen	Henry H, Lannoy D, Maboudou P, Seguy D, Dine T, Pigny P, Odou P. Addition of Regular Insulin to Ternary Parenteral Nutrition: A Stability Study. Pharmaceutics 2021 ;13, 458.
4603	tidningen	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4635	tidningen	Mohr A, Erdnöß F, Krämer I. Physicochemical stability of human insulin 1 I.U./mL infusion solution in 50 mL polypropylene syringes. Pharmaceutical Technology in Hospital Pharmacy 2021 ; 6(1): 20210005.
4650	Laboratorium	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021
4651	tidningen	De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pascual P, De Miguel M, Campino A. Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units. Eur J Pediatr 2021 ;180,1169–1176.
4698	tidningen	Ayari G, D'Huart E, Vigneron J, Demoré B. Y-site compatibility of intravenous medications commonly used in intensive care units : laboratory tests on 75 mixtures involving nine main drugs. Pharmaceutical Technology in Hospital Pharmacy 2022 ; 7(1): 20220002
4742	tidningen	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4837	tidningen	De Silva, D.T.N Petrovski M, Strunk T, Mukadam N, Page Sharp N, Moore B.R, Batty K.T. Physicochemical compatibility of caffeine citrate and caffeine base injections with parenteral medications used in neonatal intensive care settings. Eur J Clin Pharmacol 2024 ; 80:1079–1087.

4845	tidningen	De Silva D.T.N, Strunk T, Petrovski M, Page-Sharp M, Moore B.R, Batty K.T. The Physicochemical Compatibility of Sildenafil Injection with Parenteral Medications Used in Neonatal Intensive Care Settings. Pharmaceutics 2024 ;1 6, 419.
4904	tidningen	Hamelin A, Thompson-Desormeaux F, Elliott A, Friciu M, Forest JM, Leclair G. Y-site simulation compatibility study of 10% calcium salts with various injectable solutions during toxicological resuscitation. EJHP 2023
4924	tidningen	Senarathna G, Strunk T, Petrovski M, Woodland S, Martinez J, Chuang V, Batty K. Physical compatibility of lipid emulsions and intravenous medications used in neonatal intensive care settings EJHP 2023 2025;32:
5044	Laboratorium	Actrapid 100 unités internationales/ml, solution injectable en flacon. - Résumé des caractéristiques du produit. Novo Nordisk A/S 2007
5048	Laboratorium	NATRECOR® (nesiritide) lyophilized powder for intravenous use - Highlights of prescribing information. 2012
5054	Laboratorium	POLTEOFİLİN 400 MG/500 ML INJECTABLE SOLUTION FOR I.V. INFUSION - Summary of Product Characteristics. POLİFARMA İLAÇ SAN. VE TİC. A.Ş. 2018



Förklaringar

	Glukosnedsättande		injektion
	Varunamn		Lösningars stabilitet
	Behållare		Molekyl
	Koncentration		Temperatur
	Förvaring		Stabilitets varaktighet
	biologiskt likartat		motstridiga uppgifter
	Hänvisningar		Polyvinylklorid
	Natriumklorid 0,9 %		Skyddas från ljus
	Dag		Timma
	□ Dianéal® PD4 1.36% glucose (Baxter)		Ej angiven
	Physionéal® 1.36 (Baxter)		Polyetylen
	Ingen		Polypropylen och polyetylen
	Spruta polypropen		Ljus
	Stabilitet i blandningar		Lösningsmedel
	Substans		Glas
	Faktorer som påverkar stabiliteten		Filtrering
	Orsakar		Adsorption
	Etylenvinylacetat		Kompatibilitet
	Kompatibel		Glukos 5 %
	Omedelbar nederbörd		Oförenlig
	Omedelbar grumlighet		Kemisk instabilitet
	Parenteral nutrition (med lipider)		Vatten för injektion
	Ringer-laktatlösning		Ospecificerad inkompatibilitet
	Parenteral nutrition (binär blandning)		Grumlighet på en timme
	Färgändring efter 24 timmar		Utfällning efter 4 timmar
	Utfällning efter 1 timme		Glukos 10 %
	Administreringssätt		Intravenös
	Långtidsinfusion		Intramuskulär
	Subkutan		Intraperitoneal
	Långvarig subkutan infusion		Hänvisningar



Förklaringar